Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

What Is the NAD+ Salvage Pathway? NAMPT and NMN Explained

Conceptual two-stage recycling pathway, with an initial molecular component incorporated into an intermediate and then into a larger final assembly.

The salvage pathway rebuilds NAD+ from nicotinamide (NAM), the fragment left behind when NAD+-consuming enzymes finish with the coenzyme. Two enzymes carry it out. Nicotinamide phosphoribosyltransferase (NAMPT) condenses NAM with phosphoribosyl pyrophosphate (PRPP) to produce nicotinamide mononucleotide (NMN), and nicotinamide mononucleotide adenylyltransferase (NMNAT) adenylates NMN to NAD+[1][2]. In mammals this recycling route, not synthesis from amino acids, is the major source of the NAD+ pool[1].

Why Cells Recycle NAD+ Instead of Making It from Scratch

NAD+ carries two workloads that pull against each other. It is the hydrogen carrier that redox enzymes depend on, and it is a signalling molecule that modulates NAD+-sensing enzymes and so influences processes from energy metabolism to cell survival[3]. Redox use and signalling consumption are not the same event. In redox reactions NAD+ acts as a hydrogen carrier[3]; the enzymes that feed salvage instead cleave the coenzyme and release NAM[1]. The released NAM is the nicotinamide moiety of NAD+, and CD38, CD157, the PARPs and the NAD-dependent deacetylases (sirtuins) are the consumers that produce it[1][2]. Sirtuins transfer an acetyl group from their substrate protein to the ADP-ribose moiety of NAD+, splitting the coenzyme into NAM and O-acetyl-ADP-ribose[1]. NAMPT then condenses that NAM with PRPP to rebuild NMN, so salvage recovers the nicotinamide end of NAD+ rather than starting from tryptophan[2].

That consumption sets the economics. Rebuilding NAD+ from NAM takes two reactions. Building NAD+ from tryptophan is a longer de novo route that in mammals is described mainly in the liver and kidney, and predominantly in the liver[2]. Recycling is the shorter option, and it is why NAM functions as a substrate rather than as waste.

Step 1: NAMPT Converts Nicotinamide to NMN

Cutaway cell with abstract NAMPT symbols in the nucleus and cytoplasm, plus separate symbols outside the cell membrane.

Intracellular NAMPT catalyses the condensation of PRPP with NAM to yield NMN and pyrophosphate (PPi) when ATP is present[2]. This is the first step of salvage, and both the pathway overview and the enzyme reference describe NAMPT as its rate-limiting enzyme[1][2].

The enzyme has two forms that should not be treated as interchangeable. Intracellular NAMPT (iNAMPT) runs the recycling reaction inside cells and is not confined to one compartment: in 3T3-L1 preadipocytes and HepG2 hepatocytes, GFP-NAMPT appeared in both the nucleus and the cytoplasm, was excluded from the nucleus immediately after mitosis and migrated back as the cell cycle progressed, and shifted toward the nucleus under genotoxic, oxidative or dicarbonyl stress[4]. Extracellular NAMPT (eNAMPT) — formerly called PBEF1 and known as visfatin in its circulating form — is secreted by many cell types, notably adipocytes[2]. eNAMPT circulates as a dimer, but as a monomer it has pro-inflammatory effects that are independent of NAD+, while the dimeric form protects against them[2]. An eNAMPT measurement therefore says nothing directly about salvage flux, and an iNAMPT measurement says nothing about the circulating enzyme.

Step 2: NMNAT Adds the Adenylate to Make NAD+

Conceptual six-subunit enzyme assembly in a nucleus, two-subunit assembly in cytoplasm and four-subunit assembly in a mitochondrion.

NMNAT reversibly catalyses the conversion of NMN and ATP to NAD+[5]. Three isoforms divide the reaction by compartment: NMNAT-1, a homohexamer, in the nucleus; NMNAT-2, a homodimer, in the cytoplasm; and NMNAT-3, a homotetramer, in the mitochondria[5]. Nuclear localisation fits the demand pattern, since some salvage enzymes appear concentrated in the nucleus, which may compensate for the high rate of NAD+ consumption in that organelle[1].

The step is also where the "rate-limiting" label becomes ambiguous. The pathway overview assigns it to NAMPT[1]; the NMNAT review abstract calls NMNAT a rate-limiting enzyme[5]. Neither source resolves which step constrains flux in a named tissue, so a claim about the limiting step should specify the model and the measurement behind it.

Where NMN Sits in the Pathway

NMN is the immediate precursor of NAD+ in salvage[1], which makes it an intermediate rather than the pathway’s output. Because one enzyme produces it and the next consumes it, its steady-state level reflects the balance between NAMPT output and NMNAT throughput.

A measurement trap follows. Being made inside a cell and getting into one are separate questions: Slc12a8 encodes a sodium-dependent transporter that carries NMN but not nicotinamide riboside, is highly expressed in the murine small intestine, and its knockdown abolishes NMN uptake in vitro and in vivo[6]. That evidence comes from mouse intestine and cell models, so it establishes a route rather than a universal mechanism[6].

Salvage vs. De Novo and Preiss-Handler Synthesis

Three routes feed the NAD+ pool, and they differ mainly in starting material. De novo synthesis starts from amino acids; salvage recycles preformed components such as NAM back to NAD+[1]. Salvage itself uses three pyridine precursors — nicotinic acid (NA), nicotinamide (NAM) and nicotinamide riboside (NR)[1]. The nicotinic acid route has its own name, the Preiss-Handler pathway, and runs through nicotinic acid mononucleotide (NaMN) and nicotinic acid adenine dinucleotide (NaAD) before the nicotinic acid moiety is amidated to a nicotinamide moiety to form NAD+[1].

Tissue distribution separates the routes in practice. Most tissues make NAD+ by salvage, while the liver carries much more tryptophan-based de novo synthesis[1]. The kidney and macrophages are instead highlighted for the nicotinic acid route[1], which is salvage from that precursor rather than de novo synthesis from tryptophan. A liver sample and a muscle sample are not measuring the same mixture of pathways, which matters when comparing NAD+ values across studies.

Nicotinamide Riboside and the NRK Route

NR is one of the three salvage precursors[1], but it does not run through the NAMPT reaction; it has a kinase route of its own[7]. That route is a phosphorylation step: NRK1 and NRK2 phosphorylate NR to NMN, which is then adenylated to NAD+[8]. ATP serves as the phosphodonor — NRK2 is ATP-specific, whereas NRK1 phosphorylates NR effectively with ATP or GTP — and the reaction resolves to ADP plus NMN[8]. In human Nrk1 structures solved with NR and a hydrolysis-resistant ATP analogue, the γ phosphate is positioned for potential in-line transfer to the 5′ oxygen of NR[8]. NRK-2 (NMRK2) is a muscle-specific beta1-integrin binding protein abundantly expressed in skeletal muscle, with only trace amounts in healthy cardiac muscle, and it was first identified as a regulator of myoblast differentiation that enhances NAD+ levels[7].

The abstract supports a muscle-enriched kinase linked to NAD+ enhancement, but not a quantitative share of a tissue’s NAD+ that comes from NR rather than from NAM[7]. Transport is a separate question: Slc12a8 is selective for NMN over NR[6]. For NR, overexpression in HEK293 cells showed that the equilibrative nucleoside transporters ENT1, ENT2 and ENT4 import it, while the concentrative transporters CNT1–CNT3 did not, and imported NR was readily metabolised to NAM[9]. That is a cell-line result about transporter identity, not a tissue-level flux measurement.

What the Evidence Covers: Cells, Animals, and Human Data

The mechanism described above rests on enzyme characterisation and pathway description, and the type of preparation limits what each result can support. Purified-enzyme work establishes the reaction chemistry and the substrates consumed and released. Cell-culture work establishes that the step operates inside living cells and where the isoforms sit. Animal models establish tissue-level behaviour in that species.

Claims about raising NAD+ rest on a different and weaker footing. NAD+ concentration is reported to decline in tissues of aged animals, and strategies to increase NAD+ availability have shown promise in rodents, including for age-related degeneration, while human data remain limited[10]. Where human measurements exist they are blood measurements: in a 12-week randomised, double-blind, placebo-controlled trial, 30 healthy subjects were assigned to an NMN arm (n = 15) or a placebo arm (n = 15), NAD+ and related metabolites were measured in whole blood, and whole-blood NAD+ rose significantly with NMN[11]. That is a circulating-metabolite result in healthy volunteers, not a tissue NAD+ measurement or a clinical outcome. Restoration of NAD+ in old or diseased animals can promote health and extend lifespan in those models, which is what drives the search for NAD-boosting molecules[3]. Those are animal and preclinical findings, and they do not license reading a NAD+ value as a human diagnostic result.

Reading the Pathway in Lab Data

The pathway offers three analytes in sequence — NAM, NMN, NAD+ — and the choice of readout decides which question gets answered. A total NAD+ value reports pool size rather than turnover. Isotope-tracer work that quantified synthesis and breakdown found NAD fluxes varying widely across tissues, high in small intestine and spleen and low in skeletal muscle, and in the traced cell lines NAD was made from nicotinamide and consumed largely by PARPs and sirtuins[12].

NAM and NMN bracket NAMPT, so measuring them describes the substrate and intermediate pools feeding the step rather than the size of the NAD+ pool. NAM is the fragment released by NAD+-consuming enzymes and the material NAMPT condenses, and NMN is the immediate precursor NMNAT converts[1]. A shift in either analyte can reflect precursor supply, enzyme throughput or consumption upstream, and the number alone does not separate them. NAMPT activity measured in a lysate reports catalytic capacity under assay conditions, not flux through intact cells, which is the quantity the tracer approach was built to measure[12]. A NAM, NMN or NAMPT activity value is therefore interpretable only against the same assay, sample matrix and normalisation; the readouts are not interchangeable, and none of them is a diagnostic result. Bulk tissue NAD+ mixes cell types and compartments, and better tools are still needed to resolve NAD+ content of specific cells and subcellular compartments; the threshold at which depletion causes physiological consequences in a given tissue also remains undetermined[10]. Because NMNAT isoforms sit in different compartments, the same NMN pool can be routed differently depending on where it sits[5].

Four variables separate a supported statement from an overgeneralised one when reading salvage data: which precursor was supplied, which enzyme step was measured, which compartment was sampled, and which model produced the result.

Related research: What Is NAD+: Redox Cofactor for Cellular Metabolism; What Is the NAD+/NADH Ratio?; NAD+.

Research Use Only. This article is provided for laboratory research and educational purposes only. It does not describe or endorse human or veterinary dosing, administration, compounding, diagnosis or treatment, and it is not purchasing guidance.

References

  1. Nicotinamide adenine dinucleotide — Wikipedia
  2. Nicotinamide phosphoribosyltransferase (NAMPT) — Wikipedia
  3. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence (Cell Metab. 2018) — abstract
  4. Nuclear transport of nicotinamide phosphoribosyltransferase is cell cycle-dependent in mammalian cells (2019) — abstract
  5. NMNAT expression and its relation to NAD metabolism (2011) — abstract
  6. Slc12a8 is a nicotinamide mononucleotide transporter (Nat Metab. 2019) — abstract
  7. Nicotinamide riboside kinase 2: a unique target for skeletal muscle and cardiometabolic diseases (2024) — abstract
  8. Nicotinamide riboside kinase structures reveal new pathways to NAD+ (PLoS Biol. 2007) — full text
  9. Equilibrative Nucleoside Transporters Mediate the Import of Nicotinamide Riboside and Nicotinic Acid Riboside into Human Cells (Int J Mol Sci. 2021) — abstract
  10. Age-related NAD+ decline (Exp Gerontol. 2020) — abstract
  11. Oral administration of nicotinamide mononucleotide is safe and efficiently increases blood NAD+ in healthy subjects (Front Nutr. 2022) — abstract
  12. Quantitative Analysis of NAD Synthesis-Breakdown Fluxes (Cell Metab. 2018) — abstract